CLASS PERIOD: November 22, 2024 to July 21, 2025 NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the F ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers (the "Complaint"). Should You Join This Class Action ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Background - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5]. - The misleading statements resulted in investors suffering damages when the true details about Replimune's business and operations were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. following a significant drop in stock price after the FDA issued a Complete Response Letter regarding its Biologics License Application for RP1 [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal rights [1][2]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [6]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives violated federal securities laws by making false or misleading statements regarding the IGNYTE trial's prospects [4]. - It is claimed that the defendants overstated the trial's prospects, leading to the FDA deeming it inadequate, which resulted in misleading statements about the company's business and operations [4]. Group 3: Stock Market Impact - Following the FDA's Complete Response Letter on July 22, 2025, Replimune's stock plummeted over 73% during intraday trading [5].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. for alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be inadequate and poorly controlled by the FDA [2]. - It is alleged that the defendants' statements about Replimune's business and operations were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial, overstating its prospects despite known material issues, leading to the FDA deeming the trial inadequate [2] - Defendants' statements about Replimune's business and operations were claimed to be materially false and misleading, lacking a reasonable basis at all relevant times [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Replimune Group, Inc. about a class action lawsuit due to alleged misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 22, 2024, to July 21, 2025 [3]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, leading to misleading statements about Replimune's business and operations [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Replimune securities between November 22, 2024, and July 21, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4].

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...